全文获取类型
收费全文 | 214408篇 |
免费 | 20155篇 |
国内免费 | 8111篇 |
专业分类
耳鼻咽喉 | 1263篇 |
儿科学 | 4882篇 |
妇产科学 | 2941篇 |
基础医学 | 38441篇 |
口腔科学 | 3992篇 |
临床医学 | 13787篇 |
内科学 | 37775篇 |
皮肤病学 | 3568篇 |
神经病学 | 17178篇 |
特种医学 | 3879篇 |
外国民族医学 | 63篇 |
外科学 | 15691篇 |
综合类 | 25725篇 |
现状与发展 | 41篇 |
预防医学 | 9173篇 |
眼科学 | 2569篇 |
药学 | 30527篇 |
27篇 | |
中国医学 | 7104篇 |
肿瘤学 | 24048篇 |
出版年
2024年 | 549篇 |
2023年 | 3517篇 |
2022年 | 6954篇 |
2021年 | 8896篇 |
2020年 | 7487篇 |
2019年 | 8424篇 |
2018年 | 8066篇 |
2017年 | 7935篇 |
2016年 | 7671篇 |
2015年 | 9179篇 |
2014年 | 12950篇 |
2013年 | 15151篇 |
2012年 | 13086篇 |
2011年 | 15476篇 |
2010年 | 13078篇 |
2009年 | 12503篇 |
2008年 | 11991篇 |
2007年 | 10686篇 |
2006年 | 9696篇 |
2005年 | 8293篇 |
2004年 | 7258篇 |
2003年 | 6167篇 |
2002年 | 4795篇 |
2001年 | 4087篇 |
2000年 | 3349篇 |
1999年 | 3058篇 |
1998年 | 2631篇 |
1997年 | 2398篇 |
1996年 | 2084篇 |
1995年 | 1763篇 |
1994年 | 1514篇 |
1993年 | 1289篇 |
1992年 | 1069篇 |
1991年 | 978篇 |
1990年 | 832篇 |
1989年 | 689篇 |
1988年 | 586篇 |
1987年 | 461篇 |
1986年 | 474篇 |
1985年 | 875篇 |
1984年 | 892篇 |
1983年 | 617篇 |
1982年 | 682篇 |
1981年 | 553篇 |
1980年 | 450篇 |
1979年 | 385篇 |
1978年 | 301篇 |
1977年 | 234篇 |
1976年 | 218篇 |
1975年 | 149篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
161.
162.
Béla Nagy Zsolt Bene Zsolt Fejes Sonya L. Heltshe David Reid Nicola J. Ronan Yvonne McCarthy Daniel Smith Attila Nagy Elizabeth Joseloff György Balla János Kappelmayer Milan Macek Scott C. Bell Barry J. Plant Margarida D. Amaral István Balogh 《Journal of cystic fibrosis》2019,18(2):271-277
Background
We have recently shown that human epididymis protein 4 (HE4) levels correlate with the severity of cystic fibrosis (CF) lung disease. However, there are no data on how HE4 levels alter in patients receiving CFTR modulating therapy.Methods
In this retrospective clinical study, 3 independent CF patient cohorts (US-American: 29, Australian: 12 and Irish: 19 cases) were enrolled carrying at least one Class III CFTR CF-causing mutation (p.Gly551Asp) and being treated with CFTR potentiator ivacaftor. Plasma HE4 was measured by immunoassay before treatment (baseline) and 1–6?months after commencement of ivacaftor, and were correlated with FEV1 (% predicted), sweat chloride, C-reactive protein (CRP) and body mass index (BMI).Results
After 1?month of therapy, HE4 levels were significantly lower than at baseline and remained decreased up to 6?months. A significant inverse correlation between absolute and delta values of HE4 and FEV1 (r?=??0.5376; P?<?.001 and r?=??0.3285; P?<?.001), was retrospectively observed in pooled groups, including an independent association of HE4 with FEV1 by multiple regression analysis (β?=??0.57, P?=?.019). Substantial area under the receiver operating characteristic curve (ROC-AUC) value was determined for HE4 when 7% mean change of FEV1 (0.722 [95% CI 0.581–0.863]; P?=?.029) were used as classifier, especially in the first 2?months of treatment (0.806 [95% CI 0.665–0.947]; P?<?.001).Conclusions
This study shows that plasma HE4 levels inversely correlate with lung function improvement in CF patients receiving ivacaftor. Overall, this potential biomarker may be of value for routine clinical and laboratory follow-up of CFTR modulating therapy. 相似文献163.
164.
C. Knipfer F. Wagner K. Knipfer G. Millesi J. Acero J.A. Hueto E. Nkenke 《International journal of oral and maxillofacial surgery》2019,48(6):841-846
The aim of this study was to evaluate learners’ acceptance of a webinar for continuing medical education that was instigated by the International Association of Oral and Maxillofacial Surgeons (IAOMS). A live, interactive webinar on orthognathic surgery was broadcast via the Internet. The learners’ acceptance of the webinar was evaluated using a standardized, validated questionnaire (Student Evaluation of Educational Quality, SEEQ). One hundred and fifty-three participants attended the webinar; 55 participants (46 male, nine female) completed the questionnaire. The mean age of the respondents was 41.6 ± 10.0 years. The age of male and female respondents did not differ significantly. The respondents were spread over five continents, with the highest number from Brazil. The SEEQ showed a high level of acceptance for almost all subscales. There was no statistically significant difference between male and female respondents concerning acceptance of the webinar (P = 0.614). The wide distribution of participants shows the potential for webinars as facilitators of barrier-free distribution of knowledge. The webinar was well accepted by the attendees independent of sex, specialty, and work experience. However, the sex ratio reflects the underrepresentation of women in oral and maxillofacial surgery. 相似文献
165.
166.
《Arquivos brasileiros de cardiologia》2020,115(2):207
BackgroundTakotsubo syndrome (TTS) is an acquired form of cardiomyopathy. National Brazilian data on this condition are scarce. The Takotsubo Multicenter Registry (REMUTA) is the first to include multicenter data on this condition in Brazil.ObjectiveTo describe the clinical characteristics, prognosis, in-hospital treatment, in-hospital mortality, and mortality during 1 year of follow-up.MethodsThis is an observational, retrospective registry study including patients admitted to the hospital with diagnosis of TTS and patients admitted for other reasons who developed this condition. Evaluated outcomes included triggering factor, analysis of exams, use of medications, complications, in-hospital mortality, and mortality during 1 year of follow-up. A significance level of 5% was adopted.ResultsThe registry included 169 patients from 12 centers in the state of Rio de Janeiro, Brazil. Mean age was 70.9 ± 14.1 years, and 90.5% of patients were female; 63% of cases were primary TTS, and 37% were secondary. Troponin I was positive in 92.5% of patients, and median BNP was 395 (176.5; 1725). ST-segment elevation was present in 28% of patients. Median left ventricular ejection fraction was 40 (35; 48)%. We observed invasive mechanical ventilation in 25.7% of cases and shock in 17.4%. Mechanical circulatory support was used in 7.7%. In-hospital mortality was 10.6%, and mortality at 1 year of follow-up was 16.5%. Secondary TTS and cardiogenic shock were independent predictors of mortality.ConclusionThe results of the REMUTA show that TTS is not a benign pathology, as was once thought, especially regarding the secondary TTS group, which has a high rate of complications and mortality. (Arq Bras Cardiol. 2020; 115(2):207-216) 相似文献
167.
目的 建立裸鼠鼻咽癌转移模型并探讨 E-选择素(ELAM-1)与鼻咽癌转移的相关性。方法 将鼻咽癌5-8F细胞悬液注射于裸鼠左后肢爪垫,观察裸鼠状态、成瘤情况并测量裸鼠体重及移植瘤长短径;采用连续病理切片苏木精-伊红染色观察移植瘤及转移情况,将16只人鼻咽癌荷瘤裸鼠分为转移组和非转移组;采用免疫组织化学法检测两组移植瘤组织中ELAM-1的表达。 结果 16只裸鼠均成瘤,成瘤率为100.0%,其中10只裸鼠出现转移瘤,转移率为62.5%。建模前,两组裸鼠体重差异无统计学意义[(13.83±0.56)g vs (14.62±0.30) g,t=1.026,P=0.071]。建模后4~7周,裸鼠瘤体体积呈指数增长,且转移组移植瘤增长速度较非转移组快,非转移组裸鼠瘤体体积小于转移组[(198.91 ± 163.29) mm3 vs (268.76 ±174.31) mm3,t=4.376,P=0.005]。ELAM-1在鼻咽癌裸鼠移植瘤、淋巴结转移灶及远处转移灶中的表达均为阳性,主要表达于细胞膜。转移组移植瘤光密度值高于非转移组(0.4497±0.0705 vs 0.0435±0.0082,t=4.388,P=0.001)。结论 本研究成功构建稳定性好、转移率高的鼻咽癌裸鼠移植瘤转移模型,且ELAM-1在裸鼠移植瘤中高表达,可促进鼻咽癌裸鼠移植瘤生长和转移。 相似文献
168.
《Journal of thoracic oncology》2021,16(9):1449-1460
Pulmonary immune-related adverse events represent rare but potentially severe side effects of immunotherapies. Diagnosis is often challenging, as symptoms and imaging features are not specific and may mimic other lung diseases, thus potentially delaying appropriate patient management. In this setting, an accurate imaging evaluation is essential for a prompt detection and correct management of these drug-induced lung diseases. The purpose of this article is to review the different types of pulmonary immune-related adverse events, describe their imaging characteristics on both high-resolution computed tomography and positron emission tomography/computed tomography and stress their underlying diagnostic challenge by presenting the mimickers. 相似文献
169.
《European journal of surgical oncology》2021,47(12):3105-3112
BackgroundDetails of perioperative outcomes and survival after gastric cancer surgery in prior transplant recipients have received minimal research attention.MethodsWe performed an observational cohort study using the database of 20,147 gastric cancer patients who underwent gastrectomy at a single gastric cancer center in Korea. Forty-one solid organ recipients [kidney (n = 35), liver (n = 5), or heart (n = 1)] were matched with 205 controls using propensity score matching.ResultsOperation time, blood loss, and postoperative pain were similar between groups. Short-term complication rates were similar between transplantation and control groups (22.0% vs. 20.1%, P = 0.777). Transplantation group patients with stage 1 gastric cancer experienced no recurrence, while those with stage 2/3 cancer had significantly higher recurrence risk compared to the controls (P = 0.049). For patients with stage 1 cancer, the transplantation group had a significantly higher rate of non-gastric cancer-related deaths compared to the controls (19.2% vs. 1.4%, P = 0.001). For those with stage 2/3 cancer, significantly lower proportion of the transplantation group received adjuvant chemotherapy compared to the control group (26.7% vs. 80.3%, P < 0.001). The transplantation group had a higher (albeit not statistically significant) rate of gastric cancer-related deaths compared to the controls (40.0% vs. 18.0%, P = 0.087).ConclusionTransplant recipients and non-transplant recipients exhibited similar perioperative and short-term outcomes after gastric cancer surgery. From long-term outcome analyses, we suggest active surveillance for non-gastric cancer-related deaths in patients with early gastric cancer, as well as strict oncologic care in patients with advanced cancer, as effective strategies for transplant recipients. 相似文献
170.
驱动基因的发现及针对驱动基因的靶向治疗已显著提高了肺癌患者的生存质量和时间,但目前对于BRAF、HER2、MET、RET等少见驱动基因改变肺癌患者的靶向药物的选择仍然较少。近年来免疫检查点抑制剂在肺癌治疗中取得了一定的疗效,但因为少见驱动基因突变的肺癌患者本身样本量少,开展大规模临床随机对照试验尚存在一定的困难,目前此类患者接受免疫检查点抑制剂治疗的疗效情况仍不明确。本文将对目前已掌握的免疫检查点抑制剂治疗BRAF、HER2、MET、RET等少见驱动基因改变肺癌患者的临床研究结果进行综述,以期在一定程度上为临床工作提供一些依据和参考。 相似文献